Eli Lilly have at least one repurposed drug in Phase 3 trial to treat COVID : https://investor.lilly.com/news-releases/news-release-details/lilly-begins-phase-3-clinical-trial-baricitinib-hospitalized
Baricitinib is owned by Incyte, which popped about $4B USD in MC on the news its product was being trialled. I would expect a similar pop for PAA if MPL gets to Phase 3, say $6B AUD. So my rough calculation is PAA gets to $20 a share BEFORE MPLs effectiveness is proven (or not).
THEN, I’ll know the pressure the holders of 2 million shares are feeling this weekend.
Clinical Trials, page-301
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $97.22M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.0¢ | 19.5¢ | $89.3K | 450.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 615899 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 148691 | 6 |
View Market Depth
| Last trade - 10.57am 30/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |